A growing body of evidence supports the idea that a single dose of the human papillomavirus (HPV) vaccine is sufficient to protect most people.[1] In Fiji, more than 30,000 girls aged 9–12 years were vaccinated with the quadrivalent 4vHPV vaccine in 2008/2009, with more than 60% receiving at least one dose (14% only one dose, 13% only two doses, 35% three doses).[1] The effectiveness of the vaccine against oncogenic HPV 16/18 genotypes was evaluated after eight years in a retrospective cohort study in young pregnant women.[1] Efficacy values for one, two, and three doses were 81% (95% CI: 48-93%), 100% (95% CI: 100-100%), and 89% (95% CI: 64-96%), respectively.[1] A single dose of 4vHPV was highly effective against HPV genotypes 16 and 18 after eight years.[1] Experts worry that there is not yet enough evidence to support a single dose recommendation.[1]